Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Clinical trial NCT02427451 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02427451
- Sponsor
- Kerry Rogers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-03
- Primary completion
- 2021-12-24
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.